On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039

Psychopharmacology

Volumn 212, Issue 4, 2010, Pages 523-535

  Pałucha Poniewiera, Agnieszka ^a   Wierońska, Joanna M ^a   Brański, Piotr ^a   Stachowicz, Katarzyna ^a   Chaki, Shigeyuki ^b   Pilc, Andrzej ^a,c  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

AMPA receptors; Antidepressant drugs; Forced swim test; Group II mGlu receptors; Locomotor activity; LY341495; MGS0039; Olfactory bulbectomy; Serotonergic receptors; Tail suspension test

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; AMITRIPTYLINE; AMPA RECEPTOR; CITALOPRAM; FENCLONINE; METABOTROPIC RECEPTOR 2; METERGOLINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; RITANSERIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; MALE; MORNING DOSAGE; MOUSE; NONHUMAN; OLFACTORY BULBECTOMY; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM;

EID: 78651343705     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1978-5     Document Type: Article

References (45)

1. Artigas F, Romero L, de Montigny C, Blier P (1996) Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci 19:378-383
2. Bespalov A, Jongen-Rêlo AL, van Gaalen M, Harich S, Schoemaker H, Gross G (2007) Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: Reversal by antipsychotic drugs. J Pharmacol Exp Ther 320:944-950
3. Chaki R, Yoshikawa S, Hirota T, Shimazaki M, Maeda KN, Yoshimizu T, Yasuhara A, Sakagami K, Okuyama S, Nakanishi S, Nakazato A (2004) MGS0039: A potent and selective group II metabotropic glutamate receptor antagonist with antidepressantlike activity. Neuropharmacology 46:457-467
4. Conn PJ, Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237
5. Conn PJ, Lindsley CW, Jones CK (2009) Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol Sci 30:25-31
6. Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29:571-625
7. Detke MJ, Rickels M, Lucki I (1995) Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121:66-72
8. Flor PJ, Battaglia G, Nicoletti F, Gasparini F, Bruno V (2002) Neuroprotective activity of metabotropic glutamate receptor ligands. Adv Exp Med Biol 513:197-223
9. Forster EA, Cliffe LA, Bill DJ, Dover GM, Jones D, Reilly Y, Flether A (1995) A pharmacological profile of the selective silent 5- HT1A receptor antagonist WAY 100635. Eur J Pharmacol 281:81-88
10. González-Maeso J, Ang RL, Yuen T, Chan P, Weisstaub NV, López- Giménez JF, Zhou M, Okawa Y, Callado LF, Milligan G, Gingrich JA, Filizola M, Meana JJ, Sealfon SC (2008) Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 452:93-97
11. Harkin A, Kelly JP, Leonard BE (2003) A review of the relevance and validity of olfactory bulbectomy as a model of depression. Clin Neurosci Res 3:253-262
12. Hensler JG (2002) Regulation of 5-HT1A receptor function in brain following agonist or antidepressant administration. Life Sci 72:1665-1682
13. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR, Humphrey PPA (1994) VII. International union of pharmacology classification of receptors for 5- hydroxytryptamine (serotonin). Pharmacol Rev 46:157-203
14. Karasawa J, Shimazaki T, Kawashima N, Chaki S (2005) AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 1042:92-98
15. Kawashima N, Karasawa J, Shimazaki T, Chaki S, Okuyama S, Yasuhara A, Nakazato A (2005) Neuropharmacological profiles of antagonists of group II metabotropic glutamate receptors. Neurosci Lett 378:131-134
16. Kelly JP,WrynnAS, Leonard BE (1997) The olfactory bulbectomized rat as a model of depression: An update. Pharmacol Ther 74:299-316
17. Klodzinska A, Bijak M, Chojnacka-Wojcik E, Kroczka B, Swiader M, Czuczwar SJ, Pilc A (2000) Roles of group II metabotropic glutamate receptors in modulation of seizure activity. Naunyn- Schmied Arch Pharmacol 361:283-288
18. Klodzinska A, Tokarski K, Bijak M, Pilc A (2002) Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol Biochem Behav 73:327-332
19. Koe BK, Weissman A (1966) P-Chlorophenylalanine: A specific depletory of brain serotonin. J Pharmacol Exp Ther 154:499-516
20. Leonard BE, Tuite M (1981) Anatomical, physiological, and behavioral aspects of olfactory bulbectomy in the rat. Int Rev Neurobiol 22:251-286
21. Marek GJ, Wright RA, Schoepp DD, Monn JA, Aghajanian GK (2000) Physiological antagonism between 5-hydroxytryptamine (2A) and group II metabotropic glutamate receptors in prefrontal cortex. J Pharmacol Exp Ther 292:76-87
22. Middlemiss DN, Price GW, Watson JM (2002) Serotonergic targets in depression. Curr Opin Pharmacol 2:18-22
23. Miyata S, Hirano S, Kamei J (2004) Diabetes attenuates the antidepressant-like effect mediated by the activation of 5-HT1A receptor in the mouse tail suspension test. Neuropsychopharmacology 29:461-469 (Pubitemid 38365923)
24. Nowak G, Partyka A, Palucha A, Szewczyk B, Wieronska JM, Dybala M, Metz M, Librowski T, Froestl W, Papp M, Pilc A (2006) Antidepressant-like activity of CGP 36742 and CGP 51176, selective GABAB receptor antagonists, in rodents. Br J Pharmacol 149:581-590
25. O'Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, Page ME, Lucki I (2007) Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology (Berl) 192:357-371
26. O'Neill MF, Heron-Maxwell C, Conway MW, Monn JA, Ornstein P (2003) Group II metabotropic glutamate receptor antagonists LY341495 and LY366457 increase locomotor activity in mice. Neuropharmacology 45:565-574
27. Ornstein PL, Arnold MB, Bleisch TJ, Wright RA, Wheeler WJ, Schoepp DD (1998) [3H]LY341495, a highly potent, selective and novel radioligand for labeling group II metabotropic glutamate receptors. Bioorg Med Chem Lett 8:1919-1922
28. Palucha A, Branski P, Szewczyk B, Wieronska JM, Klak K, Pilc A (2005) Potential antidepressant-like effect of MTEP, a potent and highly selective mGluR5 antagonist. Pharmacol Biochem Behav 81:901-906
29. Palucha A, Pilc A (2007) Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol Ther 115:116-147
30. Pilc A, Klodzinska A, Branski P, Nowak G, Palucha A, Szewczyk B, Tatarczynska E, Chojnacka-Wójcik E, Wieronska JM (2002) Multiple MPEP administrations evoke anxiolytic- and antidepressant-like effects in rats. Neuropharmacology 43:181-187
31. Pilc A, Chaki S, Nowak G, Witkin JM (2008) Mood disorders: Regulation by metabotropic glutamate receptors. Biochem Pharmacol 75:997-1006
32. Redmond AM, Kelly JP, Leonard BE (1997) Behavioural and neurochemical effects of dizocilpine in the olfactory bulbectomized rat model of depression. Pharmacol Biochem Behav 58:355-359
33. Romero L, Hervás I, Artigas F (1996) The 5-HT1A antagonist WAY- 100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci Lett 219:123-126
34. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 301:805-809
35. Shutoh F, Hamada S, Shibata M, Narita M, Shiga T, Azmitia EC, Okado N (2000) Long term depletion of serotonin leads to selective changes in glutamate receptor subunits. Neurosci Res 38:365-371
36. Skolnick P, Popik P, Trullas R (2009) Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 30:563-569
37. Stachowicz K, Chojnacka-Wójcik E, Klak K, Pilc A (2007a) Anxiolytic-like effect of group III mGlu receptor antagonist is serotonin-dependent. Neuropharmacology 52:306-312
38. Stachowicz K, Golembiowska K, Sowa M, Nowak G, Chojnacka- Wójcik E, Pilc A (2007b) Anxiolytic-like action of MTEP expressed in the conflict drinking Vogel test in rats is serotonin dependent. Neuropharmacology 53:741-748
39. Stachowicz K, Klodzinska A, Palucha-Poniewiera A, Schann S, Neuville P, Pilc A (2009) The group III mGlu receptor agonist ACPT-I exerts anxiolytic-like but not antidepressant-like effects, mediated by the serotonergic and GABA-ergic systems. Neuropharmacology 57:227-234
40. Steru L, Chermat R, Thierry B, Simon P (1985) Tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology (Berl) 85:367-370
41. Ure J, Baudry M, Perassolo M (2006) Metabotropic glutamate receptors and epilepsy. J Neurol Sci 247:1-9
42. Wieronska JM, Pilc A (2009) Metabotropic glutamate receptors in the tripartite synapse as a target for new psychotropic drugs. Neurochem Int 55:85-97
43. Wieronska JM, Szewczyk B, Branski P, Palucha A, Pilc A (2002) Antidepressant-like effect of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist in the olfactory bulbectomized rats. Amino Acids 23:213-216
44. Yoshimizu T, Chaki S (2004) Increased cell proliferation in the adult mouse hippocampus following chronic administration of group II metabotropic glutamate receptor antagonist, MGS0039. Biochem Biophys Res Commun 315:493-496
45. Yoshimizu T, Shimazaki T, Ito A, Chaki S (2006) An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology 186:587-593